Date: 11 May 2021 Forum: Australian Patent Office Delegate: Ranganath Subbarayan Background Mr Arieni was a former colleague of one of the named inventors (Mr Fry) of Innovation...
01 Mar 2021 | EU | Biocon and Viatris announced that the CHMP has adopted a positive opinion recommending the marking authorisation of Abevmy® (biosimilar bevacizumab). If...
23 Feb 2021 | In its Q4 2020 investor presentation, Fresenius Kabi announced it will launch its biosimilar adalimumab in Australia in Q2 2021 and in Brazil in Q3 2021....
13 Feb 2021 | Saudi Arabia's Tabuk Pharmaceuticals announced it has reached an exclusive licensing and distribution agreement with Korea's Prestige Biopharma for the...
Date: 16 February 2021Forum: Australian Patent OfficeDelegate: Kevin Restrick Background Under Australian law, business methods are not patent eligible because they are not...
As discussed in Part 1 of this blog series, TGA has invited submissions by 23 March 2021 on its consultation paper released last Thursday designed to facilitate indication...
In honour of UN International Day of Women and Girls in Science Last Thursday was the International Day of Women and Girls in Science, marking 6 years since the United Nations...
04 Feb 2021 | Roche reported a huge erosion of its year on year CER growth in key areas, attributing this decline to COVID-19 impacts and biosimilars. Roche reported the YoY CER...
Under Australian law, patent infringement proceedings may be started in the Australian Federal Court only by a patentee or an exclusive licensee.[1] When it comes to determining...
TGA has invited submissions on its consultation paper released last Thursday designed to facilitate indication "repurposing", a phrase coined by TGA to describe the Australian...
29 Jan 21 | EU | The CHMP recommended 13 medicines for approval. Among the recommendations were two bevacizumab biosimilars, Mabxience's Alymsys® and STADA's Oyavas®. 01 Feb 21 |...
25 Jan 21 | Samsung Bioepis announced the opening of its new headquarters in Incheon. The building was complete in December 2020, and will house approximately 1000 new employees,...
18 Jan 21 | Prestige Biopharma announced it is set for an IPO in early February 2021. The IPO is expected to be worth US $348 million, with the majority of the funds to be...
07 Jan 21 | ADQ announced it will acquire Pharmax Pharmaceuticals, as well as investing in a minority stake in Biocon Biologics. 13 Jan 21 | Kamada announced it has entered into...
On 5 November 2020, the High Court of Australia refused a special leave application by Mylan Health Pty Ltd to appeal the decision of the Full Federal Court (FFC) in which three...
05 Jan 21 | EU | The Centre for Biosimilars reported a study presented at the 2020 San Antonio Breast Cancer Symposium found strong uptake of Amgen's Kanjinti (biosimilar...
27 Dec 20 | CN | Innovent announced China's NMPA has approved Byvasda® (biosimilar bevacizumab) for the additional indication of adult recurrent glioblastoma. 30 Dec 20 |...
21 Dec 20 | Celltrion announced Ph III trials of its proposed ustekinumab biosimilar CT-P43 will be completed by the second half of 2022. Celltrion also announced plans to launch...
Supply of essential oil for topical use infringes method of treatment patent claims Justice Nicholas’ 96-page judgment in John Hood v Bush Pharmacy Pty Ltd [2020] FCA 1686 raises...
12 Dec 20 | Biopharma supplier Alexion announced it will be acquired by AstraZeneca. The acquisition is expected to close in Q3 2021 for total consideration to Alexion...
24 Nov 20 | Novartis released its annual report 'Meet Novartis Management 2020'. In the report, Novartis announced that GP2411 (biosimilar denosumab candidate) has commenced Ph...
On 01 December NPS Medicine Wise published its annual list of the top 10 PBS drugs by cost to the Australian government. Biologics dominated the list, taking 7 of the top 10...
The Generic and Biosimilar Medicines Association announced it has appointed Ms Jane Halton AO PSM as its inaugural Independent Chair. Halton will bring a wealth of experience to...
24 Nov 20 | Novartis released its annual report 'Meet Novartis Management 2020'. In the report, Novartis announced that GP2411 (biosimilar denosumab candidate) has commenced Ph...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
